Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Diverse data matters for Alzheimer’s biomarkers because the science of detecting early Alzheimer’s disease has been built almost exclusively on research from Caucasian populations, creating blind spots that delay diagnosis and miss crucial biological differences across racial and ethnic groups. When biomarkers—the physical or chemical signatures of disease in the brain and blood—are developed from a narrow demographic, they become less accurate for everyone else. A Black patient with Alzheimer’s may have cerebrospinal fluid biomarker levels that look different from a White patient with the same disease stage, yet the diagnostic thresholds used in clinics were calibrated on predominantly white study populations. This mismatch means missed diagnoses, delayed treatment, and the perpetuation of health disparities in a disease that disproportionately affects older adults across all communities.
The problem is quantifiable and urgent. Only 8% of participants in industry-sponsored Alzheimer’s drug trials were Black or African American, 6% were Asian, and 11% were Hispanic or Latino—proportions that fail to reflect the actual burden of dementia across the United States. When researchers developed the most advanced early detection tools, they did so largely without ensuring that these tools worked equally well for everyone. The result is a biomarker science that is simultaneously too narrow and too confident—narrow because it represents a small slice of human genetic and environmental diversity, and confident because decades of research have validated these markers within that slice.
Table of Contents
- How Clinical Trials Exclude Racial and Ethnic Minorities
- Racial and Ethnic Differences in Alzheimer’s Biomarker Patterns
- Diagnostic Disparities and Delayed Recognition
- The Science Behind Race-Specific Biomarker Responses
- Barriers to Biomarker Research and Trial Participation
- Multi-Modal Approaches to Diverse Biomarker Detection
- The Path to Biomarker Equity in Alzheimer’s Research
- Frequently Asked Questions
How Clinical Trials Exclude Racial and Ethnic Minorities
The underrepresentation of racial and ethnic minorities in Alzheimer’s biomarker research begins with clinical trials, where inclusion criteria, recruitment practices, and trial design inadvertently filter out diverse participants. The numbers tell a stark story: in FDA-approved drug trials, only 8% of participants were Black or African American, a figure that stands in sharp contrast to the fact that Black Americans develop Alzheimer’s disease at nearly twice the rate of White Americans. Asian participants made up just 6% of these trials, and Hispanic or Latino participants 11%—despite Hispanics and Latinos representing 19% of the U.S. population.
These disparities don’t occur randomly; they reflect structural barriers including lack of awareness about trials, mistrust of medical research rooted in historical exploitation, geographic isolation from research centers, and language barriers that are rarely addressed by study teams. Even when diversity recruitment efforts improve, biomarker-specific barriers emerge. When researchers examined willingness to undergo amyloid PET imaging—one of the most important diagnostic tools for detecting Alzheimer’s pathology—they found striking racial and ethnic differences: 86% of Asian participants were willing to undergo the scan, compared with 72% of White participants, 70% of Black participants, and 67% of Hispanic or Latino participants. A 19-percentage-point gap between the highest and lowest groups means that in a diverse community of 100 cognitively concerned older adults, the willingness to undergo advanced neuroimaging differs sharply by race and ethnicity. This variation reflects not only differing comfort levels with invasive procedures but also practical barriers like transportation, time off work, and access to imaging centers—factors that compound the existing trial underrepresentation problem.
Racial and Ethnic Differences in Alzheimer’s Biomarker Patterns
When biomarker research does include diverse participants, it reveals a crucial finding: the biological signatures of Alzheimer’s disease are not identical across racial and ethnic groups. African American individuals, for instance, have significantly lower levels of cerebrospinal fluid t-tau and p-tau181 compared with White individuals at the same cognitive stage and Alzheimer’s disease severity. This isn’t a measurement error or a confounding variable to be controlled away—it suggests that race-dependent biological mechanisms shape how Alzheimer’s pathology manifests in the body.
If diagnostic thresholds for these biomarkers were set using predominantly White research participants, they will be too high for African American patients, potentially missing early disease and delaying diagnosis by months or years. The implication is profound: the same cerebrospinal fluid biomarker value might signal preclinical Alzheimer’s disease in a Black patient and normal aging in a White patient, depending on how the thresholds were originally established. Research has confirmed that race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers, meaning that the predictive power of a biomarker—its ability to forecast cognitive decline—depends on the patient’s racial background. This creates a scenario where a patient from an underrepresented group may have biomarkers that fall within the “normal” range on a clinically available test, yet still be on a trajectory toward cognitive decline, while another patient with different biomarker values but the same prognosis might receive an earlier diagnosis and treatment.
Diagnostic Disparities and Delayed Recognition
The real-world consequence of limited biomarker diversity is diagnostic delay, a gap measured in months or years. Hispanic patients experience an average 12-month delay in Alzheimer’s disease and related dementias (ADRD) diagnosis compared with non-Hispanic White patients—a delay that matters enormously when disease-modifying treatments are available and effective only in early stages. For Black women, the diagnostic delay intersects with another disparity: increased ADRD risk due to higher prevalence of vascular risk factors like hypertension and type 2 diabetes, combined with unique social and environmental pressures including chronic stress, systemic racism, and unequal access to preventive healthcare.
A Black woman with early cognitive changes might attribute them to stress or aging, her healthcare provider might not screen for dementia as aggressively, and the biomarker tools available might not flag her as high-risk because those tools were never adequately tested in her demographic. The 12-month delay for Hispanic patients is not merely a statistical abstraction—it translates to 12 months of progressive brain changes without treatment, 12 months in which family members may not understand what is happening, and 12 months in which opportunities for early intervention are lost. For patients enrolled in clinical trials or early-stage research programs, time matters critically: some disease-modifying drugs show benefit only when initiated in preclinical or very early symptomatic stages. A diagnostic delay of a year can mean the difference between eligibility for a treatment and ineligibility, between slowing decline and watching it accelerate.
The Science Behind Race-Specific Biomarker Responses
Understanding why biomarkers differ across racial and ethnic groups requires examining the intersection of genetics, environment, and social factors—a complexity that cannot be resolved by analyzing a single population. Genetic variation across human populations is well established, and Alzheimer’s disease susceptibility genes show different frequencies and penetrance in different ancestry groups. The APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer’s disease, has different prevalence rates across racial and ethnic groups: it is carried by roughly 25% of Black Americans, 15% of White Americans, and 10% of East Asian Americans. Yet APOE4 carriers do not all develop Alzheimer’s disease, and the age at onset and rate of cognitive decline vary significantly across populations, suggesting that genetic background modulates the gene’s effect.
Beyond genetics, environmental and social determinants create distinct biological profiles. Chronic stress from racial discrimination, environmental toxin exposure that may be unequally distributed across neighborhoods, cardiovascular disease prevalence, and dietary patterns all influence the development and manifestation of Alzheimer’s disease. When researchers develop biomarkers using predominantly White cohorts, they inadvertently calibrate these tests to the genetic and environmental context of those populations. Applying those same thresholds to a genetically and environmentally distinct population can produce false negatives—results that suggest disease is absent when it is actually present—or false positives that send people down unnecessary diagnostic pathways.
Barriers to Biomarker Research and Trial Participation
The underrepresentation of diverse groups in Alzheimer’s biomarker research is not accidental; it reflects systemic barriers embedded in how research is conducted and funded. Historically, African Americans and other minorities have been subjected to unethical research without informed consent, from the Tuskegee syphilis study to forced sterilizations to experimental vaccine trials. This history creates justified medical mistrust, and when research institutions do not actively address this legacy through transparent communication, community engagement, and demonstrable commitment to the benefit of study participants, recruitment of diverse cohorts remains difficult. Language barriers are another structural problem: biomarker studies are typically designed and conducted in English, with enrollment materials, informed consent documents, and study visits conducted in English, effectively excluding or disadvantaging people whose primary language is Spanish, Mandarin, Cantonese, or other languages.
Geographic and socioeconomic barriers compound recruitment challenges. Major Alzheimer’s research centers are concentrated in well-resourced urban areas and research universities, often far from the rural and underserved communities where many older adults—particularly Black and Hispanic populations—reside. Clinical trial participation requires time away from work, transportation, and the flexibility to attend multiple visits and testing sessions. These requirements are more easily met by affluent, employed populations with stable housing and reliable transportation than by populations experiencing poverty or housing instability. A biomarker study that requires participants to travel to an academic medical center for PET imaging and lumbar puncture will enroll few participants from neighborhoods without reliable public transportation or those working multiple jobs.
How Diverse Data Improves Biomarker Detection
Recent research initiatives are beginning to address the diversity gap through more inclusive and sophisticated study designs. Duke University’s multi-modal biomarker research project (2025-2026) is integrating diffusion MRI and functional MRI data with other markers in diverse participant cohorts, moving beyond the single-biomarker approach that characterized earlier research. Multi-modal approaches combine multiple types of biomarkers—structural brain imaging, functional connectivity patterns, cerebrospinal fluid markers, and blood-based biomarkers—to create a more complete picture of early neurodegeneration. This strategy is particularly important for diverse populations because it reduces reliance on any single marker that might be calibrated to a particular population.
Blood-based biomarkers have emerged as a potential solution to some diversity and accessibility challenges, since they require only a simple blood draw rather than invasive lumbar puncture or expensive PET imaging. Five widely validated plasma biomarkers are now identified: p-tau217, p-tau181, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and the Aβ42/40 ratio. These markers can be measured in community settings and primary care offices, potentially democratizing early detection and reducing the barriers that prevent people in underserved communities from accessing biomarker testing. However, even these blood-based markers require validation across diverse populations to ensure they perform equally well, and early evidence suggests that racial and ethnic differences in biomarker levels may be present for plasma markers as well.
The Path to Biomarker Equity in Alzheimer’s Research
Addressing the diversity crisis in Alzheimer’s biomarker research requires both immediate practical changes and long-term structural reform. On the immediate level, researchers must deliberately recruit diverse participants, conduct community engagement before studies launch, translate materials into multiple languages, and situate research in community settings rather than exclusively in academic centers. On a deeper level, the research and clinical community must acknowledge that biomarker thresholds and diagnostic cutoffs may need to be race-specific or population-specific, rather than assuming that a single threshold works equally well for everyone.
Recent studies examining the generalizability of Alzheimer’s disease plasma biomarkers in diverse genetic ancestries confirm that biomarker performance varies by ancestry, and researchers are now working toward ancestry-informed interpretation of results. The integration of genomic, biomarker, and social or environmental data from diverse individuals represents the emerging standard for refining clinical diagnoses. This approach recognizes that Alzheimer’s disease is not a single disease entity but rather a syndrome with multiple biological pathways and that these pathways may be engaged differently across populations with different genetic backgrounds and life experiences. For a Hispanic patient with a 12-month diagnostic delay, for a Black woman with elevated vascular risk, or for an Asian American with different biomarker levels than expected, equity in Alzheimer’s diagnosis depends on research and clinical tools that are calibrated to their specific biology and context, not borrowed from a population that does not represent them.
Frequently Asked Questions
Why would biomarker levels differ between racial and ethnic groups?
Biomarker differences reflect both genetic variation across human populations and distinct environmental and social factors including chronic stress, neighborhood toxin exposure, and cardiovascular disease prevalence. African Americans have significantly lower cerebrospinal fluid t-tau and p-tau181 levels than White Americans at the same disease stage, suggesting biological pathways that differ by ancestry.
What does a 12-month diagnostic delay mean for an Alzheimer’s patient?
A 12-month delay means missing early intervention opportunities when disease-modifying drugs are most effective, progressive brain changes occurring without treatment, and family members potentially misinterpreting early cognitive changes as normal aging. For Hispanic patients who experience this delay on average, it can mean the difference between treatment eligibility and ineligibility.
Can blood tests solve the diversity problem in Alzheimer’s diagnosis?
Blood-based biomarkers like p-tau217, p-tau181, NfL, and GFAP offer more accessible testing than lumbar puncture or PET imaging and can be measured in community settings. However, even plasma biomarkers show racial and ethnic variation in levels, so they still require validation and potentially race-specific interpretation thresholds.
Why are there fewer Asian and Hispanic participants in Alzheimer’s trials?
Barriers include lack of awareness about trials, medical mistrust from historical exploitation, geographic isolation from research centers, language barriers in study materials, and practical difficulties like transportation and time off work that are harder for some populations to manage.
What is the difference between clinical trials and the general biomarker research population?
Clinical trials test specific drugs and require strict inclusion criteria, while biomarker research studies participants to understand disease signatures. Both are underrepresented in diverse populations, but even when research includes diverse groups, biomarker thresholds calibrated on predominantly white cohorts may not work equally well for others.
You Might Also Like
- How Stress May Affect Alzheimer’s Risk
- Why Memory Testing Still Matters in the Biomarker Era
- Can Biomarkers Replace a Neurologist?
Related reading
For more on this topic, see NIH on health disparities in Alzheimer’s research.
